The lawmakers specifically mentioned two pending deals — AbbVie’s acquisition of Allergan and Bristol-Myers Squibb’s acquisition of Celegene.
In arguing for more scrutiny, lawmakers raised concerns that a lack of competition could cause a rise in drug prices and a lack of accessibility to essential medicines, as well as to lower-cost biosimilars and generics, according to STAT.
They also are concerned the deals may reduce innovation or push drugmakers to more aggressively pursue rebate traps.
Read the full article here.
More articles on pharmacy:
California biotech files for bankruptcy
Ohio’s Medicaid director may give results of drug pricing report in front of oversight committee
Q2 brings smaller hikes to wholesale, net drug prices
More articles on pharmacy:
California biotech files for bankruptcy
Ohio’s Medicaid director may give results of drug pricing report in front of oversight committee
Q2 brings smaller hikes to wholesale, net drug prices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.